絞り込み

17875

広告

「"Kerst JM "[Author]」の検索結果

63件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy; results from the HOVON 109 study.

A testosterone-producing Leydig cell tumor metastasis during hormonal treatment of prostate cancer.

Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients.

Sentinel Node Biopsy in Clinical Stage I Testicular Cancer Enables Early Detection of Occult Metastatic Disease.

Concurrent radiotherapy and panitumumab after lymph node dissection and induction chemotherapy for invasive bladder cancer.

Risk of diabetes after para-aortic radiation for testicular cancer.

Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Brain hyperconnectivity >10 years after cisplatin based chemotherapy for testicular cancer.

Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.

A randomized Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN).

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.

[Network of specialized sarcoma centres].

Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al.

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.

A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial.

  1. 1
  2. 2
  3. 3
  4. 4
Sort by
※並べ替えは表示に時間がかかります